Artigo de periodico

Multiparameter optimization of Trypanocidal cruzain inhibitors with in vivo activity and favorable pharmacokinetics (2022)

• Authors:
  • Pauli, Ivani
  • Rezende Junior, Celso de Oliveira
  • Slafer, Brian W.
  • Dessoy, Marco A.
  • Souza, Mariana Laureano de
  • Ferreira, Leonardo Luiz Gomes
  • Adjanohun, Abraham L. M.
  • Ferreira, Rafaela S.
  • Magalhães, Luma Godoy
  • Andricopulo, Renata Krogh
  • Duarte, Simone Michelan
  • Del Pintor, Ricardo Vaz
  • Silva, Fernando B. R. da
  • Cruz, Fabio C.
  • Dias, Luiz C.
  • Andricopulo, Adriano Defini
• USP affiliated authors: ANDRICOPULO, ADRIANO DEFINI - IFSC ; ANDRICOPULO, RENATA KROGH - IFSC ; DUARTE, SIMONE MICHELAN - IFSC ; PAULI, IVANÍ - IFSC ; SOUZA, MARIANA LAUREANO DE - IFSC ; FERREIRA, LEONARDO LUIZ GOMES - IFSC ; MAGALHÃES, LUMA GODOY - IFSC
• Unidade: IFSC
• DOI: 10.3389/fphar.2021.774069
• Subjects: DOENÇA DE CHAGAS; TRYPANOSOMA CRUZI; QUÍMICA MÉDICA; MODELAGEM MOLECULAR; PLANEJAMENTO DE FÁRMACOS
• Keywords: Chagas disease; Cruzain; Medicinal chemistry; Drug design; Multiparameter optimization; Pharmacokinetics; Molecular modeling
• Agências de fomento:
  • Financiamento CNPq
  • Financiamento CAPES
  • Financiamento FAPESP
  • Financiamento CEPID-FAPESP
• Language: Inglês
• Imprenta:
  • Publisher place: Lausanne
  • Date published: 2022
• Source:
  • Título: Frontiers in Pharmacology
  • ISSN: 1663-9812
  • Volume/Número/Paginação/Ano: v. 12, p. 774069-1-774069-21 + supplementary material, Jan. 2022

Informações sobre o DOI: 10.3389/fphar.2021.774069 (Fonte: oaDOI API)
• Este periódico é de acesso aberto
• Este artigo é de acesso aberto
• URL de acesso aberto
• Cor do Acesso Aberto: gold
• Licença: cc-by

---

Download do texto completo

Tipo	Nome	Link
	PROD032730_3062985.pdf	Direct link

How to cite

A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

• ABNT

  PAULI, Ivani et al. Multiparameter optimization of Trypanocidal cruzain inhibitors with in vivo activity and favorable pharmacokinetics. Frontiers in Pharmacology, v. 12, n. Ja 2022, p. 774069-1-774069-21 + supplementary material, 2022Tradução . . Disponível em: https://doi.org/10.3389/fphar.2021.774069. Acesso em: 27 dez. 2025.

• APA

  Pauli, I., Rezende Junior, C. de O., Slafer, B. W., Dessoy, M. A., Souza, M. L. de, Ferreira, L. L. G., et al. (2022). Multiparameter optimization of Trypanocidal cruzain inhibitors with in vivo activity and favorable pharmacokinetics. Frontiers in Pharmacology, 12( Ja 2022), 774069-1-774069-21 + supplementary material. doi:10.3389/fphar.2021.774069

• NLM

  Pauli I, Rezende Junior C de O, Slafer BW, Dessoy MA, Souza ML de, Ferreira LLG, Adjanohun ALM, Ferreira RS, Magalhães LG, Andricopulo RK, Duarte SM, Del Pintor RV, Silva FBR da, Cruz FC, Dias LC, Andricopulo AD. Multiparameter optimization of Trypanocidal cruzain inhibitors with in vivo activity and favorable pharmacokinetics [Internet]. Frontiers in Pharmacology. 2022 ; 12( Ja 2022): 774069-1-774069-21 + supplementary material.[citado 2025 dez. 27 ] Available from: https://doi.org/10.3389/fphar.2021.774069

• Vancouver

  Pauli I, Rezende Junior C de O, Slafer BW, Dessoy MA, Souza ML de, Ferreira LLG, Adjanohun ALM, Ferreira RS, Magalhães LG, Andricopulo RK, Duarte SM, Del Pintor RV, Silva FBR da, Cruz FC, Dias LC, Andricopulo AD. Multiparameter optimization of Trypanocidal cruzain inhibitors with in vivo activity and favorable pharmacokinetics [Internet]. Frontiers in Pharmacology. 2022 ; 12( Ja 2022): 774069-1-774069-21 + supplementary material.[citado 2025 dez. 27 ] Available from: https://doi.org/10.3389/fphar.2021.774069

Últimas obras dos mesmos autores vinculados com a USP cadastradas na BDPI:

• Structure-based and molecular modeling studies for the discovery of cyclic imides as reversible cruzain inhibitors with potent anti-Trypanosoma cruzi activity
• Carbamoylimidazoles as potent cruzain inhibitors with in vitro and in vivo trypanocidal activity: a structure-based drug design approach
• Discovery of potent, reversible, and competitive cruzain inhibitors with trypanocidal activity: a structure-based drug design approach
• Antitrypanosomal aminobenzimidazoles: hit to lead expansion of new chemical entities against Trypanosoma cruzi and Leishmania infantum
• SAR studies on a series of reversible competitive inhibitors of cruzain from Trypanosoma cruzi
• Convergent synthesis of proline-functionalized pyrazolopyrimidines as anti-T. cruzi bioactive compounds
• Indoles hit-to-lead for chagas disease: lessons learned within the LOLA consortium
• Discovery of highly potent and selective antiparasitic new oxadiazole and hydroxy-oxindole small molecule hybrids
• Synthesis and anti-trypanosoma cruzi activity of 3-cyanopyridine derivatives
• Structure-metabolism relationships of benzimidazole derivatives with anti-Trypanosoma cruzi activity for Chagas disease